Archive · 3 Oct 2025
Brain Cancer Study Reveals Impact on Skull and Immune Response
Imagine a really bad brain tumor called glioblastoma.
Scientists have found it doesn't just hurt the brain.
It can actually eat away at the skull, like it's crumbling.
It also messes with the stuff inside the skull bone, where our body makes important cells to fight off sickness.
The tumor sends signals that change these cells, making it harder to fight the cancer.
The scientists also learned that medicines that help with bone loss can sometimes make the tumor grow faster, and they can block treatments that help the body fight the tumor.
This study helps us understand why current treatments haven't been very successful and may lead to better ways to treat the brain cancer.
Glioblastoma affects more than just the brain.
The cancer erodes the skull and alters skull marrow.
The cancer interferes with the body's immune response.
Anti-osteoporosis drugs may worsen cancer and block immunotherapy.
The study may help improve glioblastoma treatments.
- Who
- Researchers at the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine.
- What
- A study revealing that glioblastoma can erode the skull, alter the makeup of skull marrow, and interfere with the body's immune response.
- When
- The findings were published in the journal Nature Neuroscience.
- Where
- The study was conducted on mice and patients with glioblastoma.
- Why
- To investigate the interaction between glioblastoma, the skull, and the immune system, which may explain the failure of current therapies.
- Main Focus
- Effects of glioblastoma on skull and immune response.
- Findings
- Glioblastoma erodes skull, alters marrow, interferes with immune response.
- Study Subject
- Mice and human patients.
- Skull Erosion
- Occurs along skull sutures in mice and in same anatomic areas in patients.
- Drug Effects
- Anti-osteoporosis drugs halted erosion but fueled tumor progression; blocked immunotherapy effects.
- Survival Rate
- Median survival of 15 months with standard treatment.